NTRA
Natera, Inc.
A clinical genetics company that reads traces of DNA floating in the blood to detect cancer, screen pregnancies, and monitor transplanted organs — its best-known tests include Signatera for cancer recurrence, Panorama for prenatal screening, and Prospera for transplant rejection. It began in 2004 as Gene Security Network, born from a founder's personal loss when a relative's baby died days after birth with an undetected condition. The company later renamed itself Natera, a word meant to echo "birth," "nature," and "earth."
CUSIP: 632307104HealthcareUS8 holders
Total Value
$792.46M
Total Shares
3.07M
Net Share Change
+541.3K
Activity
6 buying2 selling
Investor
Value
Shares
Weight
Change
